Wall Street brokerages expect PRA Health Sciences Inc (NASDAQ:PRAH) to report $732.96 million in sales for the current quarter, Zacks reports. Six analysts have provided estimates for PRA Health Sciences’ earnings. The highest sales estimate is $744.00 million and the lowest is $727.75 million. PRA Health Sciences reported sales of $625.40 million in the same quarter last year, which would suggest a positive year over year growth rate of 17.2%. The business is scheduled to announce its next earnings report on Wednesday, April 24th.
On average, analysts expect that PRA Health Sciences will report full-year sales of $3.14 billion for the current year, with estimates ranging from $3.11 billion to $3.17 billion. For the next fiscal year, analysts anticipate that the firm will post sales of $3.45 billion, with estimates ranging from $3.41 billion to $3.49 billion. Zacks Investment Research’s sales calculations are a mean average based on a survey of research analysts that follow PRA Health Sciences.
A number of research firms recently issued reports on PRAH. BidaskClub lowered PRA Health Sciences from a “buy” rating to a “hold” rating in a report on Friday, March 15th. Robert W. Baird lifted their target price on PRA Health Sciences from $119.00 to $122.00 and gave the stock an “outperform” rating in a report on Thursday, February 28th. SunTrust Banks lifted their target price on PRA Health Sciences to $120.00 and gave the stock an “average” rating in a report on Monday, March 4th. ValuEngine lowered PRA Health Sciences from a “buy” rating to a “hold” rating in a report on Wednesday, January 2nd. Finally, Zacks Investment Research lowered PRA Health Sciences from a “buy” rating to a “hold” rating in a report on Wednesday, January 2nd. Four equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. The company presently has an average rating of “Buy” and an average target price of $113.22.
NASDAQ:PRAH opened at $110.97 on Tuesday. The stock has a market cap of $7.23 billion, a P/E ratio of 28.24, a PEG ratio of 1.59 and a beta of 1.12. PRA Health Sciences has a 52-week low of $79.20 and a 52-week high of $121.98. The company has a current ratio of 0.87, a quick ratio of 0.87 and a debt-to-equity ratio of 1.03.
About PRA Health Sciences
PRA Health Sciences, Inc, a contract research organization, provides outsourced clinical development and data solution services to the biotechnology and pharmaceutical industries worldwide. The company operates in two segments, Clinical Research and Data Solutions. The Clinical Research segment offers product registration services, including clinical trial management, project management, regulatory affairs, therapeutic expertise, clinical operations, data and programming, safety and risk management, biostatistics and medical writing, quality assurance, and late phase services.
Recommended Story: What Does a Sell-Side Analyst Rating Mean?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for PRA Health Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PRA Health Sciences and related companies with MarketBeat.com's FREE daily email newsletter.